New Cancer Drug Pricing Rules Take Effect November 9
For many families fighting cancer, the cost of medicines is one of the heaviest burdens on the treatment journey. India's National Pharmaceutical Pricing Authority (NPPA) has announced a major move: starting November 9, 2026, trade margins on 137 non-scheduled anti-cancer drug formulations will be capped, with retail prices expected to fall by up to 70%. The news offers real relief to patients battling cancer.
The Core Change: A 30% Cap on Trade Margins
The adjustment is being introduced under the Trade Margin Rationalisation (TMR) mechanism, using Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013. Specifically:
- Trade margins on 137 notified anti-cancer formulations will be capped at 30%;
- The revised prices take effect from November 9, 2026;
- The "up to 70% reduction" is not a flat discount on every medicine — actual savings depend on each formulation's existing price and distribution margin structure.
According to the Ministry of Chemicals and Fertilizers, the measure aims to curb excessive mark-ups across the medicine supply chain and provide financial relief to patients and their families.
Which Cancer Drugs Are Covered? Patients Should Check the List
The 137 non-scheduled anti-cancer formulations were recommended by an expert committee constituted under the Directorate General of Health Services (DGHS). The committee includes oncologists, medical specialists, hospital experts and government officials, and the list will be updated periodically.
Importantly, not every cancer medicine in India is automatically covered. Patients should check the official notified list to confirm whether their prescribed formulation falls under the new rules before estimating potential savings.
How Does This Compare With the 2019 Initiative?
This is not the NPPA's first effort to control cancer medicine costs:
- 2019 initiative: Trade margins on 42 anti-cancer medicines were capped at 30%, resulting in maximum retail price reductions of up to 90% across 526 brands;
- 2026 initiative: The margin cap has been extended to 137 non-scheduled anti-cancer formulations, with prices expected to fall by up to 70%, depending on existing price structures.
The key difference is the wider coverage under the latest move. However, the two initiatives should not be compared as if every medicine will receive the same price reduction — the outcome depends on the individual formulation and its existing pricing. Patients should refer to officially published revised prices.
How Patients Can Check New Prices and Protect Their Rights
After the new rules take effect, patients and caregivers can verify prices through the following channels:
- Visit the official NPPA website to check revised prices;
- Use the government's "Pharma Sahi Daam" mobile application;
- Check updated price lists published by pharmaceutical companies, which must publish revised prices and circulate them among retailers and hospitals;
- Hospitals must prominently publish revised prices on their websites.
If a pharmacy or hospital appears to charge more than the notified price, patients can seek clarification and contact the relevant drug-control authority. State drug controllers have been directed to monitor compliance among manufacturers, distributors, pharmacies, hospitals and other medical institutions.
Could the Price Cap Lead to Cancer Drug Shortages?
Addressing concerns, the NPPA has said the measure is intended to curb excessive margins without affecting legitimate manufacturing revenues or creating artificial shortages. Pharmaceutical companies have been directed to maintain existing production and supply levels for the notified formulations. The objective is to improve affordability while protecting access to essential cancer treatments.
A Gentle Reminder
The "up to 70% reduction" varies by medicine and existing price structure. Patients should verify revised prices through official NPPA sources and consult their doctors before making any changes to prescribed cancer treatment. For everyday health management, the Xiaoshu Health App can sync with Apple Health to track relevant metrics, helping you and your family record and monitor body changes during treatment with greater ease.